New combo aims to stop lymphoma from spreading to the brain

NCT ID NCT05257018

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Apr 02, 2026 · Last updated May 01, 2026 · Updated 4 times

Summary

This study tests a chemotherapy regimen (R-CDOP) plus a drug injected into the spine (intrathecal methotrexate) in 83 adults with untreated diffuse large B-cell lymphoma who have a high risk of the cancer spreading to the central nervous system. The goal is to see if this combination lowers the chance of brain relapse within two years. Participants must be between 18 and 75 years old and have not received prior treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Cancer Hospital affilicaited to Xinjiang Medical University
NOT_YET_RECRUITING

Ürümqi, Xinjiang, China

Contact

Contact
Dongmei Ji
RECRUITING

Shanghai, Shanghai Municipality, 021, China

Contact

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA